




RealRate

PHARMACEUTICAL 2022

Pfizer INC
Rank 279 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Pfizer INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pfizer INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Pfizer INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 19% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	59,693,000
Cost of Goods Sold	30,821,000
Intangible Assets	74,354,000
Liabilities, Current	42,671,000
Liabilities, Non-Current	45,938,000
Other Assets	32,547,000
Other Compr. Net Income	-632,000
Other Expenses	6,354,000
Other Liabilities	15,404,000
Other Net Income	4,444,000
Other Revenues	81,288,000
Property and Equipment	14,882,000
Research and Development	13,829,000
Selling, General and Administrative Expense	12,703,000

Output Variable	Value in 1000 USD
Assets	181,476,000
Liabilities	104,013,000
Expenses	63,707,000
Revenues	81,288,000
Stockholders Equity	77,463,000
Net Income	22,025,000
Comprehensive Net Income	21,709,000
BaseVar	217,780,000
ECR before Limited Liability	134%
Economic Capital Ratio	256%